Expertise in
11
conditions

Dr. Crystal Denlinger

Oncology
Fox Chase Cancer Center
333 Cottman Ave, 
Philadelphia, PA 
Expertise in
11
conditions
Fox Chase Cancer Center
333 Cottman Ave, 
Philadelphia, PA 

Overview

Crystal Denlinger is an Oncologist in Philadelphia, Pennsylvania. Dr. Denlinger is highly rated in 11 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Stomach Cancer, and Fibrolamellar Carcinoma.

Her clinical research consists of co-authoring 108 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Temple University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO

Locations

Fox Chase Cancer Center
333 Cottman Ave, Philadelphia, PA 19111
Other Locations
Temple University of the Commonwealth System of Higher Education
2450 W Hunting Park Ave, Philadelphia, PA 19129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1/Phase 2
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Study Phase: Phase 2
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Biological
Study Drug: Margetuximab+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial
Enrollment Status: Terminated
Publish Date: March 25, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

108 Total Publications

Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.
Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.
Journal: Journal of the American College of Cardiology
Published: December 10, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Hossein Borghaei
Oncology
Expertise in
18
conditions
Dr. Hossein Borghaei
Oncology

Fox Chase Cancer Center Medical Group Inc

333 Cottman Ave, 
Philadelphia, PA 
 (5.5 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances

Hossein Borghaei is an Oncologist in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology
Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (5.5 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Geynisman is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Geynisman is highly rated in 18 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Expertise in
15
conditions
Dr. Elizabeth Plimack
Oncology
Expertise in
15
conditions
Dr. Elizabeth Plimack
Oncology

Temple University Hospital-Jeanes Campus

7600 Central Ave, 
Philadelphia, PA 
 (5.5 miles away)
215-728-2500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Plimack is an Oncologist in Philadelphia, Pennsylvania. Dr. Plimack is highly rated in 15 conditions, according to our data. Her top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Crystal Denlinger

How do I make an appointment with Dr. Crystal Denlinger?

You can book an appointment with Dr. Crystal Denlinger by calling their office at 215-728-4300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Crystal Denlinger a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Crystal Denlinger is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Crystal Denlinger specialize in?

While Dr. Crystal Denlinger is a Oncology, they have specific expertise in Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Stomach Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Crystal Denlinger participate in research or clinical trials?

Yes. Dr. Crystal Denlinger has published 108 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Crystal Denlinger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Crystal Denlinger accept my insurance?

Dr. Crystal Denlinger accepts most major insurance plans, including Cigna and Health Care Services Corporation. We recommend calling the office directly at 215-728-4300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Denlinger's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile